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Yevgeniy Brailovsky, DO4 , and Jawed Fareed, PhD3

Abstract
Pulmonary embolism (PE) patients have an increased prevalence and incidence of atrial fibrillation (AF). Because comorbid AF
increases risk of morbidity and mortality, we sought to investigate the role of thrombo-inflammatory biomarkers in risk stratifying
patients who experience an acute PE episode. Study participants were enrolled from a Pulmonary Embolism Response Team (PERT)
registry between March 2016 and March 2019 at Loyola University Medical Center and Gottlieb Memorial Hospital. This cohort was
divided into 3 groups: PE patients with a prior diagnosis of AF (n ¼ 8), PE patients with a subsequent diagnosis of AF (n ¼ 11), and PE
patients who do not develop AF (n ¼ 71). D-dimer, CRP, PAI-1, TAFIa, FXIIIa, A2A, MP, and TFPI were profiled using the ELISA
method. All biomarkers were significantly different between controls and PE patients (P < 0.05). Furthermore, TFPI was significantly
elevated in PE patients who subsequently developed AF compared to PE patients who did not develop AF (157.7 + 19.0 ng/mL vs.
129.0 + 9.3 ng/mL, P ¼ 0.0386). This study suggests that thrombo-inflammatory biomarkers may be helpful in indicating an acute PE
episode. Also, elevated TFPI levels may be associated with an increased risk of developing AF after a PE.
Keywords
pulmonary embolism, atrial fibrillation, biomarkers, thrombo-inflammation
Date received: 14 January 2021; revised: 31 March 2021; accepted: 12 April 2021.

Introduction
Pulmonary embolism (PE) and atrial fibrillation (AF) are both
separately associated with significant morbidity and mortality.1,2 There has been much debate in the literature regarding
how these diseases are related to one-another with some studies
suggesting that PE can be a complication of AF via thrombus
formation in the right atrium.3,4 However, new research has
recently demonstrated that patients with an acute PE episode
not only have an increased age-adjusted prevalence of AF, but
also have an increased age-adjusted incidence of AF, suggesting perhaps that increased cardiac stress associated with an
acute PE episode can increase risk of new-onset AF.5 Despite
this bidirectional relationship, little is known about how to
differentiate PE patients with pre-existing AF or patients at risk
of developing AF after an acute PE. Because PE patients with
comorbid AF, regardless of whether it is preexisting or newonset, are at an increased risk of morbidity and mortality,

developing a prediction model to understand this relationship
is important.5 We sought to investigate the role of biomarkers
of thrombo-inflammation in risk stratifying patients who present with an acute PE.
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D-Dimer

Thrombin Activatable Fibrinolysis Inhibitor Antigen
D-dimers are circulating protein fragments released from dis- (TAFIa)
integrating blood clots that are clinically measured to rule out
PE in patients with low pre-test probability.6 While an important practical screening tool for decision making in the hospital,
the D-dimer test has been further studied for its role in predicting outcomes after PE. A study done by Blamoun et al suggests
a strong correlation with increasing levels of D-dimer and inhospital mortality and PE recurrence.7 Multiple studies have
also noted this biomarker’s utility in AF as an indicator of left
atrial enlargement, thrombus formation, and cardiac stress.8-10
Overall, while not clinically relevant in AF, the D-dimer test
seems to be an indicator of the prothrombotic atmosphere created by AF. Therefore, we included this biomarker in our study
to investigate its role in PE patients with comorbid AF. We
hypothesized that D-dimer levels would be elevated in PE
patients with pre-existing or new-onset AF versus PE patients
without AF.

TAFIa is an essential part of the coagulation and fibrinolysis
process; thrombin activates TAFIa after forming a fibrin clot to
protect it against lysis.21 While it has not been extensively
studied in either disease state, a small study done by Negreva
et al reveals that TAFIa levels are reduced in the first day after
new onset AF which may explain the thromboembolic potential
of this disease immediately after its onset.10 On the other hand,
another study done by Schroeder et al exploring TAFIa’s role
in PE found that TAFI levels are increased with increasing
pulmonary occlusion rate, perhaps suggesting inefficient fibrinolysis.22 In order to study this biomarker’s role in both diseases, we measured the levels of TAFIa in PE patients in hopes
of further studying its role in risk stratifying patients with preexisting AF and new-onset AF. We hypothesized that this biomarker would also be elevated in patients with both diseases
when compared to PE patients without AF.

Factor XIIIa (FXIIIa)
C-Reactive Protein (CRP)
CRP is a liver-made protein used clinically to detect inflammation in various disease processes, including AF. The literature
notes that not only do CRP levels in AF patients predict recurrence of AF post-ablation therapy, but they also predict thromboembolic complications and mortality in AF. 11-14
Furthermore, a large epidemiological study done by Lee et al
revealed that persistently elevated CRP is associated with
increased risk of AF development.15 Like in AF patients, CRP
has also been described as a helpful tool in predicting outcomes
in PE patients.16,17 Despite its utility in AF and PE separately,
CRP has not been investigated when both diseases co-exist.
Therefore, we decided to research how this biomarker behaves
in PE patients with pre-existing and new-onset AF. We
hypothesized that this biomarker, like D-dimer, would also
be elevated in PE patients with comorbid AF when compared
to PE patients without AF.

Plasminogen Activator Inhibitor-1 (PAI-1)
PAI-1 is a primary inhibitor of activators of the fibrinolytic
pathway; therefore, elevated levels of this biomarker may serve
as an indicator of impaired fibrinolysis. While this biomarker
has not been studied in PE patients, PAI-1 levels have been
found to predict the presence of left atrial appendage thrombus
in AF patients, thus representing the prothrombotic and inflammatory state of this disease process.18-20 We included this biomarker to not only study its role in PE patients, but also to
investigate whether or not there are differences in PAI-1 levels
in PE patients with pre-existing or new-onset AF. Like our
previously mentioned biomarkers, we hypothesized that PAI1 levels would also be elevated in PE patients with AF when
compared to PE patients without AF.

FXIIIa, like TAFIa, is involved in fibrin clot stabilization,
increasing clot resistance to lysis. A study looking at polymorphisms of genes encoding FXIIIa and TAFIa found that
certain alleles of these genes can be protective against PE.23
Overall, not much more is known about FXIIIa’s role in PE or
AF. Therefore, we choose to include this biomarker in our
study to learn more about how its role in PE patients with and
without AF. Like with TAFIa, we hypothesized that this biomarker would also be elevated in patients with both diseases.

Alpha-2-Antiplasmin (A2A)
A2A is an enzyme that inactivates plasmin, thus inhibiting the
fibrinolytic process. Several studies on mice models of PE have
found that inhibiting this biomarker while administrating thrombolytic therapy was helpful in treatment of PE.24,25 Meanwhile,
the role of A2A in AF has been contraindicatory. While some
studies have shown a lower level of this biomarker in new onset
AF, other studies have noted elevated levels of this biomarker in
AF patients at higher risk of thromboembolic complications.10,26 Therefore, we decided to include this biomarker in
our investigation to further clarify A2A’s role in PE patients
with and without AF. We hypothesized that this biomarker
would be significantly elevated in patients with both diseases.

Microparticle (MP)
MPs are membrane vesicles excreted from cells in response to
activation and apoptosis. This biomarker has been well studied
in AF as a marker of hypercoagulability.27,28 Likewise, MPs
have been associated with hyperactivation of platelets in PE.29
Because this biomarker has been shown to be elevated in both
diseases separately, we hypothesized that its levels would be
even more elevated in patients with both PE and AF when
compared to PE patients without AF.
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Tissue Factor Pathway Inhibitor (TFPI)
TFPI is an important factor involved in inhibiting initiation of
coagulation process.30 The literature describes conflicting roles
of this biomarker in AF. A study done by An et al found that TFPI
is not significantly different between AF patients and controls so
long as there is no presence of LA thrombus.31 However, a study
by Yamashita et al revealed that AF paced rats had lower levels of
this biomarker, perhaps indicating a hypercoagulable state.32
Meanwhile, little research exists about TFPI in PE. It has been
postulated in the literature that low levels of TFPI are associated
with increased risk of venous thromboembolism, but a study done
by Zakai et al does not support this claim.33 To further investigate
this biomarker’s role in PE and AF, we included it in our study.

Materials and Methods
Patient Selection
This study is a retrospective observational study. Study patients
were enrolled from a Pulmonary Embolism Response Team
(PERT) registry. This registry consists of patients presenting
with an acute PE at a 2-hospital tertiary health care center
(Loyola University Medical Center and Gottlieb Memorial Hospital) between March 2016 and March 2019. Acute PE was
confirmed using either CT angiography or ventilation/perfusion
imaging. Because this was an observational study, sample size
calculation was not performed priori. At the time of PE diagnosis, discarded blood samples from these patients were assigned a
unique code to de-identify and access to protected health information was limited to the primary investigators of the study.
These samples were then analyzed for this study. Due to the
study design and due to minimal risk to the participant, a consent
waiver was obtained. The study was approved by the Institutional Review Board at Loyola University Medical Center.

Eligibility Criteria
Inclusion criteria comprised of patients who were older than
18 years and were discharged with a principal discharge diagnosis of PE (ICD-9 codes: 415.1, 415.11, 415.12, 415.19).
Exclusion Criteria were patients who did not meet the eligibility criteria were excluded.

Plasma Biomarker Analysis
All patients had blood samples collected at the time of PE diagnosis. Blood was centrifuged to separate the plasma, which was
then aliquoted and frozen for future analysis. Blood samples
were analyzed. PAI-1, D-dimer, TAFIa, FXIIIa, MP, CRP, and
TFPI were profiled using Enzyme Linked-Immuno-Sorbent
Assay (ELISA). TAFIa, A2A, and FXIIIa levels were measured
using a functional assay and were reported as a percentage of
normal controls. Normal controls were obtained from a commercial source (n ¼ 10; George King Bio-Medical, Inc., Overland Park, KS). These controls consisted of pooled normal
human plasma samples from volunteers. After data was
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Table 1. Demographics of PE Patients With Pre-Existing AF (“Pre”),
PE Patients Without AF (“PE”), and PE Patients With a Subsequent
Diagnosis of AF (“Post”).

Age
Gender
Males
Females
Race
Black
White
Hispanic
Other
BMI
PE Severity
Low Risk
Submassive
Massive
Type of AF
Persistent
Paroxysmal
Unknown

Pre

PE

Post

P-value

75.9 + 3.6

56.5 + 1.1

68.1 + 3.3

0.0006
>0.05

50% (4)
50% (4)

46% (33)
54% (38)

55% (6)
45% (5)

13% (1)
88% (7)
0
0
33.7 + 2.4

34% (24)
55% (39)
7% (5)
4% (3)
32.2 + 0.8

36% (4)
64% (7)
0
0
29.8 + 1.2

13% (1)
88% (7)
0

23% (16)
65% (46)
13% (9)

18% (2)
82% (9)
0

2
3
3

–
–
–

1
3
7

>0.05

>0.05
>0.05

>0.05

obtained, it was stored on RedCap, a secure network within the
Loyola University Medical Center’s secure research server.
Once biomarker data was collected and stored, this cohort
was divided into 3 groups: PE patients with a prior diagnosis of
AF, PE patients with a subsequent diagnosis of AF, and PE
patients who did not develop AF. Levels of the above mentioned biomarkers were then compared between these 3 groups.

Statistical Analysis
GraphPad Prism software was used to perform the statistical
analysis. Plasma levels of biomarkers were recorded as means
+ standard errors. Kruskal Wallis ANOVA tests were performed to compare levels of each biomarker in control patients,
PE patients with pre-existing AF, PE patients without AF, and
PE patients with new-onset AF. Box plots were constructed to
visualize differences of biomarker levels across different patient
groups. Two-tailed Mann-Whitney U-tests were performed to
compare biomarker levels between PE patients who did not
develop AF and those who did. Patient demographics and clinical characteristics were presented using descriptive statistics,
mean, and standard error. Demographics between these 4 groups
were analyzed using Chi-square analysis.

Results
The study cohort was divided into 3 groups: PE patients with a
prior diagnosis of AF (n ¼ 8), PE patients with a subsequent
diagnosis of AF (n ¼ 11), and PE patients who did not develop
AF (n ¼ 71). Patients with pre-existing AF were the eldest,
averaging 75.9 years, while patients with new-onset AF and no
AF averaged 68.1 years and 56.1 years, respectively
(P ¼ 0.0006). The distribution of sex, race, BMI, and PE
severity in the 3 study cohorts, as noted in Table 1, was
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Table 2. Circulating Levels of Biomarkers in the Control Group Compared to the 3 Study Groups.a
Control
PAI-1 (ng/mL)
D-Dimer (ng/mL)
TAFIa (%)
A2A (%)
FXIIIa (%)
MP (nM)
CRP (ug/mL)
TFPI (ng/mL)
a

11.5 +
89.6 +
76.4 +
161.0 +
126.0 +
7.9 +
17.7 +
60.2 +

5.1
22.3
8.5
5.9
14.0
1.9
9.2
6.7

Pre
69.9 +
5119.9 +
114.4 +
87.0 +
72.9 +
33.5 +
13.8 +
120.0 +

PE
17.2
1188.3
13.0
9.2
6.3
2.8
2.7
22.8

Post

66.5 + 5.3
8234.1 + 768.1
107.8 + 3.0
77.6 + 4.0
68.5 + 3.2
83.1 + 8.0
55.0 + 7.4
129.0 + 9.3

71.4 +
5236.5 +
114.2 +
74.2 +
58.8 +
97.9 +
22.5 +
157.7 +

P-value

13.0
1525.2
8.7
11.2
5.6
22.1
6.3
19.0

0.0001
<0.0001
0.0072
<0.0001
0.0007
<0.0001
0.0059
0.0002

The 3 study groups are divided as follows: PE patients with pre-existing AF (“Pre”), PE patients without AF (“PE”), and PE patients with new-onset AF (“Post”).

insignificant (P > 0.05). The distribution of types of AF
between the PE group with pre-existing AF and the PE group
with new-onset AF was also insignificant (P > 0.05).
Overall, circulating levels of PAI-1, D-dimer, TAFIa, MP,
CRP, and TFPI were higher than the study group compared to
the control group. As noted in Table 2, PAI-1 levels were
significantly elevated in PE patients with preexisting AF
(69.9 + 17.2 ng/mL), in PE patients without AF (66.5 +
5.3 ng/mL), and PE patients with new-onset AF (71.4 +
13.0 ng/mL) compared to controls (11.5 + 5.1 ng/mL,
P ¼ 0.0001). Likewise, D-dimer levels were significantly elevated in PE patients with preexisting AF (5119.9 + 1188.3 ng/
mL), in PE patients without AF (8234.1 + 768.1 ng/mL), and
PE patients with new-onset AF (5236.5 + 1525.2 ng/mL)
compared to controls (89.6 + 22.3 ng/mL, P < 0.0001). TAFIa
levels were also significantly elevated in PE patients with preexisting AF (114.4% + 13.0%), in PE patients without AF
(107.8% + 3.0%), and PE patients with new-onset AF
(114.2% + 8.7%) compared to controls (76.4% + 8.5%, P
¼ 0.0072). MP levels were significantly elevated in PE patients
with preexisting AF (33.5 + 2.8 nM), in PE patients without
AF (83.1 + 8.0 nM), and PE patients with new-onset AF
(97.9 + 22.1 nM) compared to controls (7.9 + 1.9 nM, P <
0.0001). CRP levels were significantly elevated in PE patients
with preexisting AF (13.8 + 2.7 ng/mL), in PE patients without AF (55.0 + 7.4 ug/mL), and PE patients with new-onset
AF (22.5 + 6.3 ug/mL) compared to controls (17.7 + 9.2 ug/
mL, P ¼ 0.0052). Lastly, TFPI levels were significantly elevated in PE patients with preexisting AF (120.0 + 22.8 ng/
mL), in PE patients without AF (129.0 + 9.3 ng/mL), and PE
patients with new-onset AF (157.7 + 19.0 ng/mL) compared
to controls (60.2 + 6.7 ng/mL, P ¼ 0.0002). See Graph 1A for
a pictorial depiction of this data.
Contrastingly, circulating levels of A2A and FXIIIa were
lower in the study group compared to the control group. As noted
in Table 2, A2A levels were significantly decreased in PE patients
with preexisting AF (87.0% + 9.2%), in PE patients without AF
(77.6% + 4.0%), and PE patients with new-onset AF (77.6% +
4.0%) compared to controls (161.0% + 5.9%, P < 0.0001). Also,
FXIIIa levels were significantly decreased in PE patients with
preexisting AF (72.9% + 6.3%), in PE patients without AF
(68.5% + 3.2%), and PE patients with new-onset AF (58.8%

Table 3. Levels of Circulating Biomarkers in PE Patients Without a
Subsequent Diagnosis of AF (“PE”) Compared to PE Patients With
New-Onset AF (“Post”).
PE
PAI-1 (ng/mL)
D-Dimer (ng/mL)
TAFIa (%)
A2A (%)
FXIIIa (%)
MP (nM)
CRP (ug/mL)
TFPI (ng/mL)

66.5 +
8234.1 +
107.8 +
77.6 +
68.5 +
83.1 +
55.0 +
129.0 +

Post
5.3
768.1
3.0
4.0
3.2
8.0
7.4
9.3

71.4 +
5236.5 +
114.2 +
74.2 +
58.8 +
97.9 +
22.5 +
157.7 +

13.0
1525.2
8.7
11.2
5.6
22.1
6.3
19.0

P-value
0.6172
0.1002
0.6172
0.3519
0.2279
0.6172
0.2463
0.0386

+ 5.6%) compared to controls (126.0% + 14.0%, P 0.0007).
See Graph 1B for a pictorial depiction of this data.
When circulating levels of all of the abovementioned biomarkers were compared between PE patients without AF and PE
patients with new-onset AF, TFPI was significantly elevated in
PE patients with a subsequent diagnosis of AF compared to PE
patients who did not develop AF (157.7 + 19.0 ng/mL vs. 129.0
+ 9.3 ng/mL, P ¼ 0.0386). All other biomarkers were insignificantly different between the 2 groups as noted in Table 3. See
Graph 2 for a pictorial depiction of this data.

Discussion
In this study, we utilized various thrombo-inflammatory biomarkers to investigate the relationship between PE and AF. Our
findings are as follows: (1) PAI-1, D-dimer, TAFIa, MP, CRP,
and TFPI were significantly increased in all 3 study groups
compared to controls; (2) A2A and FXIIIa were significantly
decreased in all 3 study groups compared to controls; and (3)
TFPI was significantly elevated in PE patients with a subsequent diagnosis of AF compared to PE patients who did not
develop AF.

A2A and FXIIIa Levels During Acute PE
It is well established that clot formation in the body increases
not only the thrombotic process but also the fibrinolytic process
in order to self-correct the underlying pathophysiology. In our
study, A2A and FXIIIa were 2 biomarkers that strayed from our
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Figure 1. A, Box plots with standard error bars showing significantly elevated levels of the following biomarkers in the 3 study groups compared
to controls. B, Box plots with standard error bars showing significantly decreased levels of the following biomarkers in the 3 study groups
compared to controls.

expected hypothesis. Levels of this biomarker were both significantly lower in the study group than the control group.
A study investigating a mice model of PE found that low levels
of A2A decreased mortality in mice after their acute PE

episode.24,34 This may suggest that low levels of A2A could
play protective role in PE patients. Therefore, we speculate that
low levels of this biomarker in our study group may be representative of the fact that a majority of our patients had either a
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TFPI
0.0386

ng/mL

400

AF. This finding, though logical, has not been supported by the
one Turkish study that explores this question; rather, in that study,
Sahan et al find that age is not associated with an increased risk of
developing AF after a PE.38 More research and is necessary to
further investigate this relationship.

300

Limitations

200
100
0
PE(-)AF

Post-PE(+)AF

Figure 2. Box plot with standard error bars comparing significant
increase in TFPI in PE patients who subsequently developed AF versus
those who did not.

low risk or submassive PE rather than a massive PE. Further
investigation with larger study groups would be necessary to
discern how A2A can be utilized to determine the risk of mortality after an acute PE.
Though we also anticipated levels of FXIIIa to be elevated
in our study group compared to our control group, our results
showed otherwise. This was less surprising than decreased levels of A2A, because a study done by Sane et al in International
Journal of Laboratory Hematology found that consumption of
coagulative factors during an acute PE episode result in low
levels of these biomarkers right after.35 Again, however, more
research with larger and more balanced study groups are necessary to understand how a PE affects levels of FXIIIa.

TFPI’s Role in Risk Stratifying PE
Of all the biomarkers studied, this research shows that elevated
TFPI levels in patients presenting with an acute PE episode are
associated with an increased risk of developing AF after a PE.
While TFPI has been shown to be elevated in patients with PE
or other venous thromboembolic disease compared to healthy
volunteers, no studies have looked at this biomarkers utility in
predicting AF in patients presenting with an acute PE episode. 36,37 Considering the increased risk of mortality in
patients with both diseases, this may provide a useful tool in
risk stratifying patients.5 However, larger studies would be
necessary to study TFPI’s role in differentiating PE patients
at an increased risk of developing AF and those who are not.

Age as a Risk Factor of New-Onset AF After PE
One last demographic difference between the 3 study groups was
the distribution of age. Those with preexisting AF were the eldest,
which is expected considering that age is one of the most significant risk factors for AF alone. Those who developed AF after a
PE were also significantly older than those who did not, suggesting that age may also be a risk factor for post-PE development of

The study limitations include unbalanced study groups and
relatively small sample sizes. Because PE patients were stratified based on their AF status after enrollment in the PERT
group, it was difficult to ensure balanced study groups. We did
not have access to patient comorbidities such as coronary artery
disease, hypertension, diabetes mellitus, chronic kidney disease, heart failure, cancer, or chronic obstructive pulmonary
disease. We also did not have access to medications, like anticoagulants, antiplatelets, beta blockers, or calcium channel
blockers, used by these patients at baseline. This information
would have given us a better understanding of confounding
variables that could have impacted the results of this study.
Using propensity score matching to compare the experimental group to the control group would have better accounted for
covariables; however, our study was limited by our use of
pooled human plasma as controls since the medical histories
of volunteers contributing to these samples were unknown.
Thus, in future studies, we would want to ensure that experimental and control groups were matched in terms of comorbidities, medications, etc. to avoid confounding variables.
This study also found a significant difference in age between
the groups. PE patients with pre-existing AF were generally older
than patients without AF at baseline. While this is reasonable
based on the fact that age is one of the most common risk factors
of AF, a more balanced distribution of patient groups in terms of
demographics would further validate these observations. Additionally, more clinical information from the time of PE diagnosis
such as heart rate, blood pressure, pulse oximetry, echocardiography data, BNP levels, and renal function would also have been
interesting to further characterize patients. Because we sought to
profile biomarkers in PE patients, we did not collect this information for our study; however, we obtain this information for
future studies. Despite these limitations, this study underscores
the importance of further investigating biomarkers that may help
stratify PE patients at risk of developing AF.

Conclusion
Various thrombo-inflammatory biomarkers like PAI-1,
D-dimer, TAFIa, MP, CRP, TFPI, A2A and FXIIIa are significantly elevated at the time of acute PE. Elevated levels of TFPI
may be associated with PE patients who are more likely to
develop new-onset AF. The clinical utility of TFPI as a risk
stratifying biomarker needs to be further investigated with
study models appropriately designed to determine this
information.
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